OKKO Health announce £2 million pre-seed round to bring sight monitoring app to European market

Posted by 

SETsquared Bristol

OKKO Health, a developer of eye health self-monitoring apps, has announced the close of a pre-seed round of £2 million to support the launch of its eye health monitoring app in Germany. The round was led by Dieter von Holtzbrinck Ventures (DvH Ventures), based in Cologne, Germany, from its Digital Health Fund. 

Stephanie Campbell wearing black top holding phone with OKKO Health appThe Bristol-based healthtech startup joined SETsquared Bristol in 2018 to support development of its range of sight monitoring apps focussing on macular degeneration.

Macular disease is the leading cause of sight loss in developed nations. It affects over 1.5 million people in the UK alone. OKKO’s apps provide patients with the ability to self-monitor their condition through a simple interactive smartphone game. Played regularly, the game can inform clinicians, and patients, of changes in visual acuity, sensitivity to contrast, distortion, and colour vision. These data points become cues for clinical intervention.

The funding supports the creation of new aggregate datasets, providing opportunities to better understand how to target treatments for macular degeneration through the deployment of AI in the form of machine learning algorithms. The ultimate aim is to make precision ophthalmology a reality, and protect sight. 

The company has created a CE marked product, co-developed with support from Innovate UK and The Macular Society in the UK. The app has now undergone beta testing, has been validated through multiple academic and clinical studies, and is being piloted by several clinical partners in the UK. Its launch in Germany will enable the gathering of market evidence for national reimbursement, a novel aspect of the German health care system, through studies in hospitals and clinics. 

Dr. Stephanie Campbell, Founder and CEO of OKKO Health said: 

“This funding will support an important foothold in the German healthcare market, a key step in our global growth. It brings us closer to our vision to get predictive eye health care into the hands of people worldwide, and protect our most valuable sense.”

Speaking of the funding, Fabian von Trotha from DvH Ventures said:

“OKKO doesn’t simply replicate the eye chart on a smartphone, it’s a whole new way of measuring sight. And the team has shown excellent traction to date, partly testament to its clinical experience. OKKO’s founder, Dr. Stephanie Campbell, has both clinical and vision science expertise, and this gives her deep, first-hand, market understanding which is hugely valuable in the digital health space.”

Dr. Claire Novorol, Chair of the OKKO Board, who also holds the role Co-founder and Chief Medical Officer at Ada Health, added:

“This funding round brings OKKO one step closer to our vision of patient enablement and precision ophthalmology. The platform enables proactive monitoring and optimal timing of medical interventions, such as the blockbuster anti-VEGF drugs. In many cases, pharmaceutical intervention can come too late for those with macular disease. By putting monitoring literally in the hands of the patients, the frequency of measurements can be dramatically increased, creating early warning signals for treatment.”

Recent News, Blogs and Stories

Hot air balloon over Clifton Suspension Bridge

SETsquared Bristol’s guide to regional business support resources

We understand that it’s tough starting out with a new startup, so we've put together this guide to the business support services we offer, as well as other options available...
Kailash Manohara Selvan from SpatialCortex with Jack Jordan Connelly at SETsquared Investment Futures event

Bristol startups pitch at SETsquared’s 20th annual investment event

Six of our companies were selected to present their startups at SETsquared’s Investment Futures 24 showcase in London this November. Investment Futures is an annual high-profile occasion that over its...
Impulsonics founders at NEC competition

Biotech startup Impulsonics awarded £300,000 Innovate UK grant

Bristol-based startup, Impulsonics has been awarded the prestigious ICURe spinout support grant of £300,000 to enable the development of its unique technology platform for biotech automation. The grant will enable...


Fast track your technology business